Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
Status:
Completed
Trial end date:
2020-05-06
Target enrollment:
Participant gender:
Summary
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the
acute treatment of agitation in schizophrenia. The BXCL501-301 study is designed to
characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of
DEX, HCl) in agitation associated with schizophrenia, schizoaffective disorder or
schizophreniform disorder.